Old drug, new hope? ivermectin tackles stubborn skin disease
NCT ID NCT07286604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested whether the drug ivermectin could safely treat post-kala-azar dermal leishmaniasis (PKDL), a skin condition that can appear after recovery from visceral leishmaniasis. Ten otherwise healthy adults with PKDL took ivermectin pills for five days each month for three months. Researchers monitored for side effects and checked if skin lesions improved. The goal was to see if ivermectin could offer a simpler, shorter treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST KALA-AZAR DERMAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)
Dhaka, 1212, Bangladesh